K562 cells were subcutaneously inoculated in M-NSG mice. a Tumor volume was measured by time. b Body weight was simultaneously checked. *Wild-type cell lines are not for sale, and only applied to construction of tumor bearing mice and in-vivo efficacy studies.

2020年11月19日 · To assess cytokine release from CAR-T cells, sorted Th9 or Tc9 CAR-T cells were stimulated by antigen-expressing tumor cells (CD19-expressing K562 cells; wild-type K562 cells served as a...

2023年5月8日 · We performed a head-to-head comparison of HLA engineering and immune checkpoint inhibition strategies in a simplified experimental setup with K562, a naturally HLA class I- and II-deficient cell...

2021年5月25日 · To test this possibility, we selected two cancer-associated ASXL1 truncations (Y591* and Y591fs), which are present in the well-characterized leukemia cell line, K562 (Extended Data Fig. 1a). To...

2016年9月21日 · To test the ability of human memory-like NK cells to control leukemia in vivo, we engrafted K562-luc (luciferase-expressing) leukemia cells in NSG mice and adoptively transferred human IL-12, IL-15, and IL-18–preactivated or control NK cells into groups of NSG mice on day 4 .

In summary, MODK562 significantly enhanced CB NK expansion and cytotoxicity, enhanced survival in a human Burkitt's lymphoma xenograft NSG model, and could be used in the future as adoptive cellular immunotherapy after umbilical CB transplantation.

K562 xenograft refers to the transplantation of K562 cells into immunocompromised mice, which allows for the study of the growth and progression of K562-derived tumors in vivo. K562 xenograft models have been widely used in cancer research to evaluate the efficacy of potential therapeutic agents against leukemia.

2017年2月1日 · In summary, MODK562 significantly enhanced CB NK expansion and cytotoxicity, enhanced survival in a human Burkitt's lymphoma xenograft NSG model, and could be used in the future as adoptive cellular immunotherapy after umbilical CB transplantation.

2014年1月1日 · Fixed gene-modified K562 can serve as effective aAPC to expand CMV-specific cytotoxic T lymphocytes for therapeutic use in patients after stem cell transplantation. Our findings have implications for broader understanding of the immune evasion mechanisms used by leukemia and other tumors.

2015年12月8日 · (Left) NSG™ mice treated with a combination of IL-15 and UCB-NK cells show significantly delayed and decreased tumor burden compared to controls treated with either PBS or IL-15 alone. Tumor load was determined by bioluminescent imaging of …